Stephens Inc. AR Has $2.71 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Stephens Inc. AR raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 721.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,398 shares of the biotechnology company's stock after acquiring an additional 64,459 shares during the period. Stephens Inc. AR's holdings in Exelixis were worth $2,710,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. Farther Finance Advisors LLC boosted its position in shares of Exelixis by 6.1% during the first quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock worth $195,000 after buying an additional 307 shares during the period. Balyasny Asset Management L.P. boosted its position in shares of Exelixis by 1.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock worth $573,000 after buying an additional 317 shares during the period. Sterling Capital Management LLC boosted its position in shares of Exelixis by 7.8% during the fourth quarter. Sterling Capital Management LLC now owns 6,627 shares of the biotechnology company's stock worth $221,000 after buying an additional 477 shares during the period. Comerica Bank boosted its position in shares of Exelixis by 0.6% during the fourth quarter. Comerica Bank now owns 87,681 shares of the biotechnology company's stock worth $2,920,000 after buying an additional 544 shares during the period. Finally, Heron Bay Capital Management boosted its position in shares of Exelixis by 1.0% during the fourth quarter. Heron Bay Capital Management now owns 70,061 shares of the biotechnology company's stock worth $2,333,000 after buying an additional 698 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded up $0.20 during trading hours on Thursday, reaching $45.01. 821,024 shares of the stock were exchanged, compared to its average volume of 2,521,689. The firm has a market capitalization of $12.27 billion, a price-to-earnings ratio of 20.45, a P/E/G ratio of 0.88 and a beta of 0.28. Exelixis, Inc. has a 52 week low of $22.20 and a 52 week high of $49.62. The stock's fifty day simple moving average is $42.84 and its 200 day simple moving average is $38.25.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the sale, the director owned 358,882 shares of the company's stock, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Sue Gail Eckhardt sold 18,838 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total value of $805,136.12. Following the sale, the director directly owned 21,380 shares in the company, valued at approximately $913,781.20. This trade represents a 46.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 458,113 shares of company stock valued at $21,024,817 over the last ninety days. 2.82% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

EXEL has been the subject of several recent research reports. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a research report on Monday, June 23rd. Morgan Stanley reiterated an "overweight" rating and set a $47.00 target price (up previously from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Guggenheim set a $45.00 target price on Exelixis and gave the stock a "buy" rating in a report on Thursday, May 15th. Finally, JMP Securities upped their target price on Exelixis from $47.00 to $50.00 and gave the stock a "market outperform" rating in a report on Monday, June 23rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.28.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.